Public procurement notice: Contract Award Notice
Published: 2021-12-28
Buyer: Oslo Universitetssykehus (OUS)
Country: NO
Contract type: Services
Procedure: Negotiated without a prior call for competition
CPV classification: 33100000 | 60100000
Estimated value: 2100000 NOK
Award criteria: Lowest price

Technical requirements: OUS has chosen to enter into a contract with Theradis Pharma without a prior contest in order to avoid critical delay to the project, as Theradis Pharma already supplies equivalent services to the consortium EU RESPONSE. EU SolidAct is financed by the EU and will form part of Europe’s contingency plan for future pandemics. It is critical to implement the platform while COVID-19 is still a pandemic, as this can both be of significance in development of new treatments that can improve survival of COVID-19, as well as enable the EU to have quicker and better trialling of relevant medicines in the even of the next pandemic.
The EU RESPONSE consortium consists in addition to the EU SolidAct of the ongoing sister study DisCoVeRy, lead by French INSERM. The plan is that EU SolidAct will start in DisCoVeRy’s footsteps, and afterwards expand and take over as the only study in the consortium. Part of this plan is to utilise DisCoVeRy’ network and logistics as much as possible in order to be able to expand quickly enough.
Theradis Pharma currently carries out medicine management and biobank logistics for the DisCoVeRy study, and has delivered these services to an exceptional quality and at a reasonable price Theradis Pharma has specialised in supporting academic studies, and is big enough to handle the project, but at the same time not too large for the project to take priority and have close follow-up. As EU SolidAct will supply medicines and collect biobank materials at many of the same study locations as DisCoVeRy, it will be cost-efficient for the consortium to use the same supplier for the two studies, which will run simultaneously for the next six months.
As the project is financed by the EU, and the procurement has a value close to the threshold value to trigger competition, we have informed the EU commission about the process along the way. We have received support for the choices described under point 4, as long as we follow Norwegian legislation and document the process along the way.
We have chosen to enter into a contract with Theradis Pharma without a prior contest in order to avoid critical delay to the project, as Theradis Pharma already supplies equivalent services to the consortium EU RESPONSE. EU SolidAct is financed by the EU and will form part of Europe’s contingency plan for future pandemics. It is critical to implement the platform while COVID-19 is still a pandemic, as this can both be of significance in development of new treatments that can improve survival of COVID-19, as well as enable the EU to have quicker and better trialling of relevant medicines in the even of the next pandemic.
The EU RESPONSE consortium consists in addition to the EU SolidAct of the ongoing sister study DisCoVeRy, lead by French INSERM. The plan is that EU SolidAct will start in DisCoVeRy’s footsteps, and afterwards expand and take over as the only study in the consortium. Part of this plan is to utilise DisCoVeRy’ network and logistics as much as possible in order to be able to expand quickly enough.
Theradis Pharma currently carries out medicine management and biobank logistics for the DisCoVeRy study, and has delivered these services to an exceptional quality and at a reasonable price Theradis Pharma has specialised in supporting academic studies, and is big enough to handle the project, but at the same time not too large for the project to take priority and have close follow-up. As EU SolidAct will supply medicines and collect biobank materials at many of the same study locations as DisCoVeRy, it will be cost-efficient for the consortium to use the same supplier for the two studies, which will run simultaneously for the next six months.
As the project is financed by the EU, and the procurement has a value close to the threshold value to trigger competition, we have informed the EU commission about the process along the way. We have received support for the choices described under point 4, as long as we follow Norwegian legislation and document the process along the way.


Winner: Theradis Pharma
Award value: 2100000
Number of bids: 1